Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT00681369
- Lead Sponsor
- AstraZeneca
- Brief Summary
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 217
Inclusion Criteria
- Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate Faslodex therapeutic strategy and treatment duration At the end of the study Describe the characteristics of patients treated with Faslodex At the end of the study
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Faslodex in treating initial breast cancer in France?
How does Faslodex compare to other aromatase inhibitors in early breast cancer management?
Which biomarkers correlate with Faslodex treatment duration in hormone receptor-positive breast cancer?
What adverse events are associated with Faslodex in real-world breast cancer patient populations?
Are there combination therapies involving Faslodex and CDK4/6 inhibitors for initial breast cancer?